Company / Total Assets
Gilead Sciences Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$59.0B
FY2025
5-year range
$59.0B / $68.0B
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#9 of 214
Health Care
What the data says
Among 214 Health Care companies, Gilead Sciences is in the top 4% for total assets. Total Assets returned to growth in FY2025 after 4 years of decline, reaching $59.0B.
Based on SEC 10-K filings.
$59.0B in FY2025 with a 5-year CAGR of -2.9%. Top quartile in the Health Care sector.
Declined from $62.1B to $59.0B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -2.2%
- 5-Year CAGR
- -2.9%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 214This company $59.0B Sector average $7.5B
▼
+690.2% above sector average
Key checks
Key Insights
- 5-year CAGR of -2.9%, indicating a declining trend.
- In FY2025, total assets increased 0.0% year-over-year.
- Ranks #9 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2017.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $59.0B | +0.0% |
| FY2024 | $59.0B | -5.0% |
| FY2023 | $62.1B | -1.7% |
| FY2022 | $63.2B | -7.0% |
| FY2021 | $68.0B | -0.7% |
| FY2020 | $68.4B | +11.0% |
| FY2019 | $61.6B | -3.2% |
| FY2018 | $63.7B | -9.4% |
| FY2017 | $70.3B | +23.4% |
| FY2016 | $57.0B | +10.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026